Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Sci ; 113(1): 205-220, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34773335

ABSTRACT

Lung adenocarcinoma (ADC) is the predominant histological type of lung cancer, and radiotherapy is one of the current therapeutic strategies for lung cancer treatment. Unfortunately, biological complexity and cancer heterogeneity contribute to radioresistance development. Karyopherin α2 (KPNA2) is a member of the importin α family that mediates the nucleocytoplasmic transport of cargo proteins. KPNA2 overexpression is observed across cancer tissues of diverse origins. However, the role of KPNA2 in lung cancer radioresistance is unclear. Herein, we demonstrated that high expression of KPNA2 is positively correlated with radioresistance and cancer stem cell (CSC) properties in lung ADC cells. Radioresistant cells exhibited nuclear accumulation of KPNA2 and its cargos (OCT4 and c-MYC). Additionally, KPNA2 knockdown regulated CSC-related gene expression in radioresistant cells. Next-generation sequencing and bioinformatic analysis revealed that STAT1 activation and nuclear phospholipid scramblase 1 (PLSCR1) are involved in KPNA2-mediated radioresistance. Endogenous PLSCR1 interacting with KPNA2 and PLSCR1 knockdown suppressed the radioresistance induced by KPNA2 expression. Both STAT1 and PLSCR1 were found to be positively correlated with dysregulated KPNA2 in radioresistant cells and ADC tissues. We further demonstrated a potential positive feedback loop between PLSCR1 and STAT1 in radioresistant cells, and this PLSCR1-STAT1 loop modulates CSC characteristics. In addition, AKT1 knockdown attenuated the nuclear accumulation of KPNA2 in radioresistant lung cancer cells. Our results collectively support a mechanistic understanding of a novel role for KPNA2 in promoting radioresistance in lung ADC cells.


Subject(s)
Adenocarcinoma of Lung/metabolism , Cell Nucleus/metabolism , Lung Neoplasms/metabolism , Phospholipid Transfer Proteins/metabolism , Radiation Tolerance , STAT1 Transcription Factor/metabolism , alpha Karyopherins/metabolism , Adenocarcinoma of Lung/genetics , Cell Line, Tumor , Feedback, Physiological , Female , Gene Expression Profiling , Gene Expression Regulation, Neoplastic/radiation effects , Gene Knockout Techniques , High-Throughput Nucleotide Sequencing , Humans , Lung Neoplasms/genetics , Neoplastic Stem Cells/metabolism , Phospholipid Transfer Proteins/genetics , STAT1 Transcription Factor/genetics , Up-Regulation , alpha Karyopherins/genetics
2.
Rapid Commun Mass Spectrom ; 34 Suppl 1: e8578, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31499585

ABSTRACT

RATIONALE: Accumulating evidence has linked prolonged exposure to heavy metals to cancer occurrence in the urinary system. However, the specific biological mechanisms responsible for the association of heavy metals with the unusually high incidence of upper tract urothelial carcinoma in Taiwan are complex and incompletely understood. METHODS: To elucidate the specific biological mechanism and identify molecular indicators of the unusually high association of upper tract urothelial carcinoma with heavy metal exposure, protein expression following the treatment of T24 human bladder carcinoma and RT4 human bladder papilloma cell line models with arsenic (As) and cadmium (Cd) was studied. Proteomic changes in these cell models were integrated with data from a human bladder cancer (BLCA) tissue proteome to identify possible protein indicators of heavy metal exposure. RESULTS: After mass spectrometry based proteomic analysis and verification by Western blotting procedures, we identified 66 proteins that were up-regulated and 92 proteins that were down-regulated in RT4 cell extracts after treatment with As or Cd. Some 52 proteins were up-regulated and 136 proteins were down-regulated in T24 cell extracts after treatment with Cd. We further confirmed that down-expression of the PML (promyelocytic leukemia) protein was sustained for at least 75 days after exposure of bladder cells to As. Dysregulation of these cellular proteins by As was associated with three biological pathways. Immunohistochemical analyses of paraffin-embedded BLCA tissue slides confirmed that PML protein expression was decreased in BLCA tumor cells compared with adjacent noncancerous epithelial cells. CONCLUSIONS: These data suggest that PML may play an important role in the pathogenesis of BLCA and may be an indicator of heavy metal exposure in bladder cells.


Subject(s)
Arsenic/adverse effects , Cadmium/adverse effects , Proteins/analysis , Urinary Bladder Neoplasms/chemically induced , Urinary Bladder Neoplasms/diagnosis , Biomarkers, Tumor/analysis , Biomarkers, Tumor/metabolism , Cell Line, Tumor , Humans , Protein Interaction Maps , Proteins/metabolism , Proteomics , Signal Transduction , Taiwan/epidemiology , Tandem Mass Spectrometry , Urinary Bladder/drug effects , Urinary Bladder/pathology , Urinary Bladder Neoplasms/epidemiology , Urinary Bladder Neoplasms/metabolism
3.
Mol Cell Proteomics ; 16(5): 799-811, 2017 05.
Article in English | MEDLINE | ID: mdl-28235782

ABSTRACT

Multiple (selected) reaction monitoring (MRM/SRM) of peptides is a growing technology for target protein quantification because it is more robust, precise, accurate, high-throughput, and multiplex-capable than antibody-based techniques. The technique has been applied clinically to the large-scale quantification of multiple target proteins in different types of fluids. However, previous MRM-based studies have placed less focus on sample-preparation workflow and analytical performance in the precise quantification of proteins in saliva, a noninvasively sampled body fluid. In this study, we evaluated the analytical performance of a simple and robust multiple reaction monitoring (MRM)-based targeted proteomics approach incorporating liquid chromatography with mass spectrometry detection (LC-MRM/MS). This platform was used to quantitatively assess the biomarker potential of a group of 56 salivary proteins that have previously been associated with human cancers. To further enhance the development of this technology for assay of salivary samples, we optimized the workflow for salivary protein digestion and evaluated quantification performance, robustness and technical limitations in analyzing clinical samples. Using a clinically well-characterized cohort of two independent clinical sample sets (total n = 119), we quantitatively characterized these protein biomarker candidates in saliva specimens from controls and oral squamous cell carcinoma (OSCC) patients. The results clearly showed a significant elevation of most targeted proteins in saliva samples from OSCC patients compared with controls. Overall, this platform was capable of assaying the most highly multiplexed panel of salivary protein biomarkers, highlighting the clinical utility of MRM in oral cancer biomarker research.


Subject(s)
Biomarkers, Tumor/metabolism , Chromatography, Liquid/methods , Mass Spectrometry/methods , Mouth Neoplasms/metabolism , Salivary Proteins and Peptides/metabolism , Calibration , Case-Control Studies , Humans , Limit of Detection , Mouth Neoplasms/diagnosis , Neoplasms, Squamous Cell/diagnosis , Neoplasms, Squamous Cell/metabolism , Reproducibility of Results
SELECTION OF CITATIONS
SEARCH DETAIL
...